Alexis Tran, DO
Urogynecology and Reconstructive Pelvic Surgery · Pasadena, CANPI 1952545220
Payments from drug & device makers
Across 35 payments — averaging $106.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Coloplast$1K
- Caldera Medical, Inc$444
- AbbVie$126
- Ironwood Pharmaceuticals, Inc$125
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$96
- plus $129 from 4 others
What the payments were for
- Travel & lodging$1,95352%
- Food & beverage$1,77948%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 10 | $1,662 |
| Coloplast | 8 | $1,150 |
| Caldera Medical, Inc | 4 | $444 |
| AbbVie | 5 | $126 |
| Ironwood Pharmaceuticals, Inc | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $96 |
| Boston Scientific | 3 | $63 |
| Axonics, Inc. | 1 | $24 |
| Bayer | 1 | $23 |
| Medline Industries LP | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,732 in reported general payments places this provider in the 40th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 42 | $28,605 |
| Trospium Chloride ErTrospium Chloride | 25 | $5,397 |
| Estradiol | 43 | $2,564 |
| Trospium Chloride | 46 | $1,926 |
| Methenamine Hippurate | 15 | $1,604 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 37 | $254 |
| Ibuprofen | 22 | $149 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $73 |
| Ciprofloxacin Hcl | 12 | $57 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $46 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Pasadena
- David KimblePasadena$11K
- Bilal KaakiRiverside$431K
- Andrew BrillSan Francisco$345K
- Tanaz FerzandiLos Angeles$344K
- Savitha KrishnanMountain View$243K
- Felicia LaneOrange$121K
- Bruce Kahnla Jolla$114K
- Christopher TarnayLos Angeles$102K
- Peter CastilloLos Gatos$95K
- Azin ShahryarinejadManhattan Beach$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.